BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.

@article{Roux2015BRAFIR,
  title={BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma.},
  author={Jennifer Roux and C{\'e}cile Pag{\`e}s and Diane Malouf and Nicole Basset Seguin and Nika Madjlessi and Monique Baccard and Christelle Comte and Alain Archimbaud and Maxime Battistella and Manuelle Viguier and Samia Mourah and Martine Bagot and Celeste Lebb{\'e}},
  journal={Melanoma research},
  year={2015},
  volume={25 6},
  pages={
          559-63
        }
}
In around 50% of melanomas, the BRAF V600 mutation, resulting in an activation of the MAP kinase pathway, is detected. BRAF inhibitors have shown remarkable activity on the disease. However, efficacy is short-lived in most cases, with a median disease-free survival of 6 months. This short duration of response could be explained by the acquisition of resistance mechanisms. Some cancers show sensitivity to the reintroduction of previously active drugs after disease progression. We carried out a… CONTINUE READING
BETA

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

BRAF Fusion as a Novel Mechanism of Acquired Resistance to Vemurafenib in BRAFV600E Mutant Melanoma.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2017